OPCH at a glance
Option Care Health, Inc. (OPCH, SEC CIK 1014739) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Option Care Health, Inc. (OPCH) reported revenue of $5.6 billion (up 15.0% from FY2024) and net income of $207.6 million. Diluted EPS was $1.27.
- As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Option Care Health, Inc. (OPCH) shares worth $1.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Pate R Carter on November 11, 2026 of 400 shares at $31.65 per share.
- In the last 90 days, OPCH insiders reported 0 open-market purchases ($0) and 2 open-market sales ($205K) on Form 4, a net sale of $205K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.6B
- +15.0% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$205K
- 13F holders
- 32 funds
- $1.5B · +1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Largest independent provider of home and alternate site infusion therapy via 196 locations in 43 states, serving complex chronic conditions
- New emphasis: Expansion of ambulatory infusion suites to 109 standalone locations, including 27 with advanced practitioner capabilities
- Strategic position: Strengthened national presence with integrated sales targeting managed care, health systems, and drug manufacturers for new product launches
- Quantitative metric: Employee count rose to 6,528 full-time and 1,738 part-time as of Dec 31, 2025, including ~2,700 nursing staff
- Noteworthy fact: Received multiple national accreditations (ACHC, PCAB, ASHP, URAC) underscoring quality and compliance in infusion services
Management Discussion & Analysis
- Revenue $5.65B, up 13.0% YoY from $5.00B driven by mid-teens growth in acute therapies and low double-digit chronic growth
- Operating margin declined to 6.0% from 6.4%; gross margin fell to 19.3% from 20.3% due to therapy mix and biosimilar adoption
- Best segment: Acute therapies with mid-teens revenue growth; Worst: Chronic therapies with higher cost mix including rare/orphan therapies
- Operating cash flow $258M down $65M; investing cash outflow $161M up $125M due to Intramed Plus acquisition; financing cash outflow $277M up $59M driven by $310M stock repurchase
- Management expects $25M-$35M negative gross profit impact in 2026; secured credit facility amendments lowered interest rate and extended maturities supporting liquidity
AI summary of the OPCH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added merger risk: October 5, 2026 Merger Agreement created approval and closing uncertainties
- Regulatory risk: HSR Act and healthcare regulatory approvals could delay or prevent consummation
- Operational risk: Merger restrictions may limit debt, acquisitions, capital expenditures, and material contracts
- Financial risk: Termination under specified circumstances could require approximately $145.96 million payment
- Legal risk: Stockholder litigation could enjoin or delay the Merger and divert management attention
Management Discussion & Analysis
- Q3 revenue $1,493.5M, up 4.1% from $1,435.0M YoY, driven by acute therapy growth
- Gross margin 19.1% vs 19.0% YoY; operating margin 6.0% vs 5.9%
- Acute therapies best performer, high-single-digit growth; CID weakest, declining from attrition and unfavorable mix
- Operating cash flow $286.2M vs $222.6M; cash $299.1M vs $232.6M at December 31, 2025
- CID headwinds expected to reduce 2026 gross profit by approximately $55M; merger expected to close first half of 2027
AI summary of the OPCH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced by Option Care Health on November 4, 2026
- Detailed quarterly figures and management commentary in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $1,493.5M, up 4.1%, with GAAP net income $57.4M, up 10.8%
- Diluted EPS $0.38, up 18.8%, while adjusted EPS reached $0.49, up 8.9%
Item EX-99.1: Item EX-99.1
- CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, valuing the company at approximately $5.8 billion
- Offer represents an approximately 37% premium to OPCH’s October 5, 2026 closing price, providing immediate cash value to shareholders
Item 1.01: Entry into a Material Definitive Agreement
- Acquisition agreed at $32.05 cash per share, subject to stockholder approval and regulatory clearances
- CD&R and McKesson investor group financing includes $2.873B equity commitments and up to $3.15B debt
Item 7.01: Regulation FD Disclosure
- Option Care Health, CD&R and McKesson announced entry into a merger agreement
- Merger agreement signals a potentially transformative ownership change for Option Care Health
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results released July 29, 2026, providing investors the company’s latest operating update
- Exhibit 99.1 contains the substantive results, including GAAP figures and non-GAAP reconciliations
Item EX-99.1: Item EX-99.1
- Q2 revenue $1.442B, up 1.9%; GAAP net income $53.9M, up 6.7%
- Adjusted EBITDA $117.5M, up 3.0%; adjusted diluted EPS $0.45, up 9.8%
AI summaries of OPCH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OPCH
Don't miss the next OPCH filing
- Alerts as it files. A push when OPCH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OPCH, by share count.
- Ask anything. An AI agent that reads every OPCH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Pate R Carter | Sell | Nov 11, 2026 | 400 | $31.65 |
| Pate R Carter | Sell | Nov 10, 2026 | 6,092 | $31.65 |
| Bhatia Prateek | A | Jul 6, 2026 | 16,386 | - |
| Bhatia Prateek | A | Jul 6, 2026 | 23,409 | - |
| Deckmann Natasha | A | May 20, 2026 | 844 | $22.23 |
| Bodem Barbara W. | A | May 20, 2026 | 8,997 | - |
| BRANDT ERIC | A | May 20, 2026 | 8,997 | - |
| KRAEMER HARRY M JANSEN JR | A | May 20, 2026 | 12,079 | $22.23 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.9B | $5.6B |
| Gross Profit | - | $1.0B | $1.1B |
| Operating Income | - | $321.8M | $337.9M |
| Net Income | - | $211.8M | $207.6M |
| Gross Margin | - | 20.6% | 19.3% |
| Op. Margin | - | 6.6% | 6.0% |
| Net Margin | - | 4.3% | 3.7% |
| Balance Sheet | |||
| Total Assets | $3.2B | $3.4B | $3.5B |
| Equity | $1.4B | $1.4B | $1.3B |
| ROE | - | 15.1% | 15.7% |
| Per Share | |||
| EPS | - | $1.23 | $1.27 |
| Cash Flow | |||
| Operating CF | - | $323.4M | $258.4M |
| CapEx | - | $35.6M | $41.3M |
Source: XBRL data in Option Care Health, Inc. (OPCH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate OPCH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 32 | $1.48B |
| Q2 2026 | 31 | $1.46B |
| Q1 2026 | 31 | $1.91B |
| Q4 2025 | 29 | $2.32B |
| Q3 2025 | 31 | $2.12B |
| Q2 2025 | 30 | $2.42B |
| Q1 2025 | 29 | $1.88B |
| Q4 2024 | 24 | $998.1M |
- Dimensional Fund Advisors+860.5K (+16%)
- Principal Financial Group+335.7K (+64%)
- Citigroup+332.8K (+108%)
- BlackRock+180.3K (+1%)
- AQR Capital Management+151.0K (+89%)
- Morgan Stanley−896.4K (-40%)
- Goldman Sachs Group−655.9K (-30%)
- JPMorgan Chase & Co−461.5K (-40%)
- Citadel Advisors LLC−436.3K (-27%)
- Millennium Management−432.5K (-17%)
- FMR LLC (Fidelity)−1.82M
- Allstate−35.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 237 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OPCH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 12, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 12, 2026 | - | Analysis | |
| 4 | May 7, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| 4 | May 4, 2026 | - | - | - |
| SC 13G | Apr 30, 2026 | - | - | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
Related Health Care companies
- AHCO · AdaptHealth Corp.Services-Home Health Care Services
- ADUS · Addus HomeCare CorpServices-Home Health Care Services
- AVAH · Aveanna Healthcare Holdings, Inc.Services-Home Health Care Services
- BTSG · BrightSpring Health Services, Inc.Services-Home Health Care Services
- CHE · Chemed CorpServices-Home Health Care Services
- EHAB · Enhabit, Inc.Services-Home Health Care Services
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
OPCH SEC filings: frequently asked questions
Are OPCH insiders buying or selling?
In the last 90 days, Option Care Health, Inc. (OPCH) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $205,472 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OPCH stock?
As of September 30, 2026, the largest Option Care Health, Inc. (OPCH) holders among the 13F filers tracked by SignalX were BlackRock ($501.2 million), Vanguard Portfolio Management LLC ($179.2 million), Vanguard Capital Management LLC ($151.5 million), Dimensional Fund Advisors ($141.9 million), State Street Corp ($138.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OPCH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Option Care Health, Inc. (OPCH) reported revenue of $5.6 billion (up 15.0% from FY2024) and net income of $207.6 million. Diluted EPS was $1.27. The figures come from the XBRL data in the 10-K.
What did OPCH report in its latest 8-K?
Option Care Health, Inc. (OPCH) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced by Option Care Health on November 4, 2026.
What are the latest OPCH SEC filings?
Option Care Health, Inc. (OPCH) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 12, 2026.
What is OPCH's SEC CIK number?
Option Care Health, Inc. (OPCH)'s SEC Central Index Key (CIK) is 1014739. EDGAR lists every OPCH filing under that number.
Ask anything about OPCH
The research agent reads OPCH's filings, financials, insider trades and 13F holders, then answers with sources.